George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, Giannelos N. Updated public health impact and cost effectiveness of recombinant zoster vaccine in Canadian adults aged 50 years and older. Pharmacoecon Open. 2024 May;8(3):481-92. doi: 10.1007/s41669-024-00483-w
Salem A, La EM, Curran D, Patterson BJ, Carrico J, Lorenc S, Hicks KA, Poston S, Carpenter CF. Cost-effectiveness of recombinant zoster vaccine for the prevention of herpes zoster in hematopoietic stem cell transplant recipients and other immunocompromised adults in the United States. Pharmacoecon Open. 2023 Nov;7(6):975-85. doi: 10.1007/s41669-023-00438-7
Russell-Smith TA, Brockbank J, Mamolo C, Knight C. Cost effectiveness of gemtuzumab ozogamicin in the first-line treatment of acute myeloid leukaemia in the UK. Pharmacoecon Open. 2021 Dec;5(4):677-91. doi: 10.1007/s41669-021-00278-3
Garbinsky D, Hunter S, La EM, Poston S, Hogea C. State-level variations and factors associated with adult vaccination coverage: a multilevel modeling approach. Pharmacoecon Open. 2021 Sep;5(3):411-23. doi: 10.1007/s41669-021-00262-x
Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4
Gupta A, El-Rami H, Barham R, Fleming A, van Hemert J, Sun JK, Silva PS, Aiello LP. Effect of phase-plate adjustment on retinal image sharpness and visible retinal area on ultrawide field imaging. Eye (Lond). 2019 Apr 1;33(4):587-91. doi: 10.1038/s41433-018-0270-5
Oldenburg CE, Keenan JD, Cevallos V, Chan MF, Acharya NR, Gaynor BD, McLeod SD, Esterberg EJ, Porco TC, Lietman TM. Microbiological cure times in acanthamoeba keratitis. Eye (Lond). 2011 Sep;25(9):1155-60. doi: 10.1038/eye.2011.126